Roles of microRNAs in preeclampsia

Lv, Yan; Lü, Cheng; Ji, Xiaohong; Miao, Zhijing; Long, Wei; Ding, Hongjuan; Lv, Mingming

doi:10.1002/jcp.27291

Cited by 138 publications

(97 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Epigenetic gene modification not only occurs in placental tissue, but also in circulating leucocytes, shed extracellular trophoblast particles, and cell-free DNA and RNA. As will be discussed below, these play an important role in fetal–maternal communication and in triggering the systemic inflammatory response [ 60 , 61 , 62 ], in which they are assisted by the presence of trophoblast plugs in the uterine arteries. Before 10 weeks of gestation, the intravascular lumen of the spiral arteries is blocked by solid trophoblast plugs, containing numerous endovascular trophoblast cells and adhesive molecules, such as matrix metallopeptidase 1 (MMP1) [ 63 ].…”

Section: Pathophysiologymentioning

confidence: 99%

“…This activation process spreads rapidly via paracrine and endocrine pathways to other nearby or distant endothelial cells [ 78 ]. As discussed above, these particles may act via intravesicular microRNAs and/or circular RNAs that, after phagocytosis by endothelial and immune cells, induce sterile inflammation and alter the production of mediators of angiogenesis and vasoactivity, such as sFLT1, VEGF, and pregnancy-associated placental protein A (PAPP-A) [ 61 , 62 , 80 ]. Many other vasoactive and immunological mediators have been studied in the maternal serum for the diagnosis or prediction of PE, and are summarized in Table 3 .…”

Section: Pathophysiologymentioning

confidence: 99%

“…The first stages of distant fetal–maternal communication occur via trophoblast invasion of the intrauterine veins and lymphatic vessels [ 50 ], during the stage when the spiral arteries are blocked with trophoblast plugs [ 63 , 64 , 65 ]. Before the activation of the intervillous arterial supply, biochemical and epigenetic signals are released into the maternal system, preparing the female organ systems to accept and accommodate the growth of the fetus [ 60 , 61 , 62 ]. Errors in this communication process can be bidirectional because the fetal signals may be inadequate and/or the maternal response may be unbalanced.…”

Section: Integrated Pathophysiology Of Pementioning

confidence: 99%

See 2 more Smart Citations

Preeclampsia Is a Syndrome with a Cascade of Pathophysiologic Events

Gyselaers

2020

JCM

View full text Add to dashboard Cite

This review integrates the currently available information on the molecular, cellular, and systemic mechanisms involved in the pathophysiology of preeclampsia. It highlights that the growth, protection, and promotion of the conceptus requires the modulation of an intact maternal immune system, communication between the mother and fetus, and adaptation of the maternal organic functions. A malfunction in any of these factors, on either side, will result in a failure of the cascade of events required for the normal course of pregnancy. Maladaptive processes, initially aiming to protect the conceptus, fail to anticipate the gradually increasing cardiovascular volume load during the course of pregnancy. As a result, multiple organ dysfunctions install progressively and eventually reach a state where mother and/or fetus are at risk of severe morbidity or even mortality, and where the termination of pregnancy becomes the least harmful solution. The helicopter view on pathophysiologic processes associated with preeclampsia, as presented in this paper, illustrates that the etiology of preeclampsia cannot be reduced to one single mechanism, but is to be considered a cascade of consecutive events, fundamentally not unique to pregnancy.

show abstract

Section: Pathophysiologymentioning

confidence: 99%

Section: Pathophysiologymentioning

confidence: 99%

Section: Integrated Pathophysiology Of Pementioning

confidence: 99%

See 1 more Smart Citation

Preeclampsia Is a Syndrome with a Cascade of Pathophysiologic Events

Gyselaers

2020

JCM

View full text Add to dashboard Cite

show abstract

“…The delay in childbearing in the developed countries adds to the risk factors associ-ated with preeclampsia such as older age, obesity, and cardiovascular disease (3). It seems that the mechanism of preeclampsia is a combination of genetic factors, epigenetics and environmental factors that contribute to its pathogenesis and pathophysiology, and its only treatment is delivery of the placenta and embryo (1,4). Clinical symptoms of the disease can be greatly attributed to placental defects, in particular, dysregulation of trophoblast cells.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of microRNA (411, 377, and 154) Expression in the Plasma and Placenta of Women with Preeclampsia

et al. 2019

View full text Add to dashboard Cite

Background: MicroRNAs (miRNA) are considered to be the regulators of the gene expression. They play an essential role in cell proliferation, apoptosis, and development. Change in their expression is associated with various pathologic disorders. Moreover, preeclampsia (PE) is a complex pregnancy-related disorder. Objectives: The purpose of this study was to determine the rate of three miRNA expressions in the placenta and plasma of healthy individuals and pregnant women with preeclamptic. Methods: Plasma and placenta samples were collected from 10 women with preeclampsia during the first trimester and third trimester of the pregnancy, and 10 healthy pregnant women who referred to Medical Genetics Center, Shiraz, Iran. The miRNA expression was investigated in the samples by real-time reverse-transcription-polymerase chain reaction analysis. Results: The expression profile of three miRNAs from the 14MC cluster was performed on 10 placenta and 40 plasma samples. Expression of miR-411 in normal and PE placenta was low; only significant differences were observed at 5% level between PE plasma and normal placenta. In addition, the expression of miR-377 was low in all samples. A high expression of miR-154 was observed in normal and PE placentas. A significant difference was detected between the placenta and PE plasma samples. Conclusions: Considering many factors affecting the amount and type of the expression of miRNAs, and based on the results of the present study, it seems miR-411, miR-377, and miR-154 are possibly appropriate candidates as novel biomarkers; however, further investigation is needed to confirm their suitability in the future studies.

show abstract

“…have been inconsistent [3][4][5][6][7][8][9][10] . Such biomarkers included those related to placental perfusion/vascular resistance, endocrine dysfunction, renal dysfunction, endothelial dysfunction, and oxidative stress 11 .…”

mentioning

confidence: 99%

Metabolomic biomarkers in midtrimester maternal plasma can accurately predict the development of preeclampsia

Lee

Kang

Lee

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Early identification of patients at risk of developing preeclampsia (PE) would allow providers to tailor their prenatal management and adopt preventive strategies, such as low-dose aspirin. Nevertheless, no mid-trimester biomarkers have as yet been proven useful for prediction of PE. This study investigates the ability of metabolomic biomarkers in mid-trimester maternal plasma to predict PE. A case–control study was conducted including 33 pregnant women with mid-trimester maternal plasma (gestational age [GA], 16–24 weeks) who subsequently developed PE and 66 GA-matched controls with normal outcomes (mid-trimester cohort). Plasma samples were comprehensively profiled for primary metabolic and lipidomic signatures based on gas chromatography time-of-flight mass spectrometry (GC-TOF MS) and liquid chromatography Orbitrap mass spectrometry (LC-Orbitrap MS). A potential biomarker panel was computed based on binary logistic regression and evaluated using receiver operating characteristic (ROC) analysis. To evaluate whether this panel can be also used in late pregnancy, a retrospective cohort study was conducted using plasma collected from women who delivered in the late preterm period because of PE (n = 13) or other causes (n = 21) (at-delivery cohort). Metabolomic biomarkers were compared according to the indication for delivery. Performance of the metabolomic panel to identify patients with PE was compared also to a commonly used standard, the plasma soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio. In the mid-trimester cohort, a total of 329 metabolites were identified and semi-quantified in maternal plasma using GC-TOF MS and LC-Orbitrap-MS. Binary logistic regression analysis proposed a mid-trimester biomarker panel for the prediction of PE with five metabolites (SM C28:1, SM C30:1, LysoPC C19:0, LysoPE C20:0, propane-1,3-diol). This metabolomic model predicted PE better than PlGF (AUC [95% CI]: 0.868 [0.844–0.891] vs 0.604 [0.485–0.723]) and sFlt-1/PlGF ratio. Analysis of plasma from the at-delivery cohort confirmed the ability of this biomarker panel to distinguish PE from non-PE, with comparable discrimination power to that of the sFlt-1/PlGF ratio. In conclusion, an integrative metabolomic biomarker panel in mid-trimester maternal plasma can accurately predict the development of PE and showed good discriminatory power in patients with PE at delivery.

show abstract

Roles of microRNAs in preeclampsia

Cited by 138 publications

References 105 publications

Preeclampsia Is a Syndrome with a Cascade of Pathophysiologic Events

Preeclampsia Is a Syndrome with a Cascade of Pathophysiologic Events

Evaluation of microRNA (411, 377, and 154) Expression in the Plasma and Placenta of Women with Preeclampsia

Metabolomic biomarkers in midtrimester maternal plasma can accurately predict the development of preeclampsia

Contact Info

Product

Resources

About